$24 Million in Grants Will Help End the HIV Epidemic

Gilead Sciences, Inc. today announced $24 million in new grants that will help reduce health disparities, improve access to quality healthcare, advance medical education and support local communities most impacted by the HIV epidemic and COVID-19 pandemic. 

Gilead confirmed the Zeroing In: Ending the HIV Epidemic program will support 116 organizations in 41 countries. 

The funding recipients will focus on advancing at least one of three focus areas: Comprehensive HIV Innovation, Digital Health Innovation, and Community Outreach and Education.

• Comprehensive HIV Innovation Programs: This includes at-home testing efforts that help close the gaps in HIV testing and prevention, supportive service programs, and comprehensive HIV prevention programs inclusive of biomedical prevention options.
• Digital Health Innovations: Strategies will address the health literacy divide in accessing digital health services, support digital access in rural areas for better outcomes for people living with HIV, or support digital health education for those with language barriers, aging populations, indigenous, migrant and stigmatized populations.
• Community Outreach and Education: Community-driven programs will provide resources for HIV community outreach workers, address the lack of culturally appropriate service options, break down barriers between communities and service providers, and reduce stigma and improve education around HIV.

“While the HIV community has made tremendous progress toward ending the HIV epidemic, the COVID-19 pandemic created barriers and amplified health inequities in the most marginalized communities,” commented Alex Kalomparis, SVP, Public Affairs, Gilead Sciences, in a press release issued on March 28, 2022. 

“We are working with organizations that will reach under-resourced communities and support them to find innovative, effective solutions. Zeroing In programs aim to increase access to HIV care and services and build on Gilead’s efforts to help end the epidemic for everyone, everywhere.”

To build on progress in local communities, Zeroing In organizations will prioritize populations most affected by the HIV epidemic. This includes projects from local organizations collaborating to end the HIV epidemic in their respective cities, states, countries, or regions.

Zeroing In builds on previous Gilead funding and grant programs while supporting organizations to increase the overall health and wellness of communities most impacted by HIV and COVID-19.

For more information on Gilead’s Zeroing In: Ending the HIV Epidemic grant program, please visit Zeroing In. A complete list of funded organizations can be found here.

Gilead Sciences, Inc. is a biopharmaceutical company with headquarters in Foster City, California, that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

PrecisionVaccinations publishes fact-checked research-based news.

Note: This news article edited Gilead’s press release for clarity and was manually curated for mobile readers.